Asunción Hervás-Morón

Dr. Asunción Hervás-Morón

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Journal of Clinical Oncology
Verified
Journal Article
Open access
YPYolanda Pardo
Yolanda Pardo
FGFerran Guedea
Ferran Guedea
FAFerrán Aguiló
Ferrán Aguiló
PFPablo Fernández
Pablo Fernández
VMVíctor Macías
Víctor Macías
MFMontserrat Ferrer
Montserrat Ferrer
Purpose: Earlier studies evaluating the effect on quality of life (QoL) of localized prostate cancer interventions included patients receiving adjuvant hormone therapy, which could have affected their outcomes. Our objective was to compare the QoL impact of the three most common primary treatments on patients who were not receiving adjuvant hormonal treatment. Patients and Methods: This was a prospective study of 435 patients treated with radical prostatectomy, external-beam radiotherapy, or brachytherapy. QoL was assessed before and after treatment with the Short Form-36 and the Expanded Prostate Cancer Index Composite. Differences between groups were tested by analysis of variance. Distribution of outcome at 3 years was examined by stratifying according to baseline status. Generalized estimating equation models were constructed to assess the effect of treatment over time. Results: Compared with the brachytherapy group, the prostatectomy group showed greater deterioration on urinary incontinence and sexual scores but better urinary irritative-obstructive results (−18.22, −13.19, and +6.38, respectively, at 3 years; P < .001). In patients with urinary irritative-obstructive symptoms at baseline, improvement was observed in 64% of those treated with nerve-sparing radical prostatectomy. Higher bowel worsening (−2.87, P = .04) was observed in the external radiotherapy group, with 20% of patients reporting bowel symptoms. Conclusion: Radical prostatectomy caused urinary incontinence and sexual dysfunction but improved pre-existing urinary irritative-obstructive symptoms. External radiotherapy and brachytherapy caused urinary irritative-obstructive adverse effects and some sexual dysfunction. External radiotherapy also caused bowel adverse effects. Relevant differences between treatment groups persisted for up to 3 years of follow-up, although the difference in sexual adverse effects between brachytherapy and prostatectomy tended to decline over long-term follow-up. These results provide valuable information for clinical decision making.

1 October 2008 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MFMontserrat Ferrer
Montserrat Ferrer
JSJosé Francisco Suárez
José Francisco Suárez
FGFerran Guedea
Ferran Guedea
PFPablo Fernández
Pablo Fernández
VMVíctor Macías
Víctor Macías
MCMulticentric Spanish Group of Clinically Localized Prostate Cancer
Multicentric Spanish Group of Clinically Localized Prostate Cancer

7 August 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FLFernando López-Campos
Fernando López-Campos
MMMargarita Martín-Martín
Margarita Martín-Martín
RFRoberto Fornell-Pérez
Roberto Fornell-Pérez
JGJuan Carlos García-Pérez
Juan Carlos García-Pérez
JDJavier Die-Trill
Javier Die-Trill
FCFelipe Couñago
Felipe Couñago
Watch and wait approach in rectal cancer: Current controversies and future directions

30 April 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
IHIvan Henriquez
Ivan Henriquez
GSGemma Sancho
Gemma Sancho
AHAsunción Hervás-Morón
Asunción Hervás-Morón
BGBenjamin Guix
Benjamin Guix
JPJoan Pera
Joan Pera
APAlfredo Polo
Alfredo Polo
To evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after radiation therapy.

1 December 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
IHIvan Henriquez
Ivan Henriquez
CSCarmen González-San Segundo
Carmen González-San Segundo
JVJesús Olivera Vegas
Jesús Olivera Vegas
CMCristina Gutiérrez Miguélez
Cristina Gutiérrez Miguélez
AHAsunción Hervás-Morón
Asunción Hervás-Morón
PÁPedro Cuesta Álvaro
Pedro Cuesta Álvaro

1 November 2009 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
AMAngel Montero
Angel Montero
RHRaúl Hernanz
Raúl Hernanz
ACAna-Belén Capuz
Ana-Belén Capuz
EFEva Fernández
Eva Fernández
AHAsunción Hervás-Morón
Asunción Hervás-Morón
ARAlfredo Ramos
Alfredo Ramos